⏰10 days left to submit your abstract for #ESGEDays2027!
Showcase your research at Europe's leading endoscopy meeting & shape the future of GI endoscopy.
🌟Travel grants, awards, publication opportunities & international recognition await top abstracts.
🔗https://t.co/aTlmGBPPmt
🔥A large lesion for #ESD!
What would be your approach to this lesion❓️
📽 Watch out for the multi-traction, multi-tunneling approach using ACI Light! 🔥
🔴 only in @endoscopyjrnl ❗️
➡️ https://t.co/w34QlVAGP7
🔵 @ESGE_news
⚪️ @ThiemeIntl
🟢 @Innov_Medicine
That was #LUCID2026 in Chicago! 🔥
Great days of advanced endoscopy, hands-on training, inspiring discussions and amazing people. 🩺🔬🤝
Proud to be part of it and share our experience in therapeutic and bariatric endoscopy. 🌎
#Endoscopy#Gastroenterology#MedEd#GiTwitter
🧩 Phenotype-driven management of #EoE at #UEGWeek2026
💊 PPI, topical steroids or diet
🔄 Switch therapy if needed
🎯 Dilatation for strictures
💉 Dupilumab for selected patients
Treatment tailored to phenotype. 👌
@my_UEG#MedTwitter#MedEd
💊 Should corticosteroids be discontinued before surgery?
📊 Data presented at #UEGWeek2026 suggest fewer organ space SSIs after discontinuation, although study heterogeneity remains an important caveat.
An interesting ✉️ for clinical practice! 🔬
#GiTwitter#MedEd@my_UEG
🔥 What has changed in #diverticulitis management from 2018 → 2026?
Less routine antibiotics, more individualized care, and important changes in recurrent disease and post-abscess management. 📚🔄
Great guideline update at #UEGWeek2026! 👏
@my_UEG#MedTwitter#Guidelines
Missed out on a chance for a HOT spot at #UEGWeek?
Tomorrow (Tuesday) walk-in sessions are available at 10:00 and 12:30.
Full details here: https://t.co/MvbmOhiICl
🔥 Excellent session on Emergencies in Upper GI at #UEGWeek2026!
Great practical insights on managing refractory and recurrent GI bleeding and where OTSC fits in the algorithm. 🩸📎
@my_UEG#MedTwitter#Endoscopy#GIbleeding
💊🚀 The obesity pharmacotherapy pipeline is exploding!
From GLP-1 ➡️ GIP/GLP-1 ➡️ GLP-1/glucagon ➡️ even triple agonists 🔥
The next generation of obesity drugs is already coming.📈
Exciting overview at #UEGWeek2026 🇪🇸
@my_UEG#MedTwitter#Obesity#GLP1
🎯 BMI doesn’t tell the whole story!
📏 Fat distribution matters especially visceral and abdominal fat.
🔥 Visceral fat is strongly linked to metabolic and liver risk 🫀🩺, even in patients with a “normal” BMI.
#UEGWeek2026 🇪🇸 in Barcelona!
@my_UEG#MedTwitter#Obesity
⚠️ Surgical risk in cirrhosis is not only about liver function, the type of surgery matters. 🏥
From low-risk procedures to high-risk open abdominal and cardiothoracic surgery: choose wisely❗️
#UEGWeek2026#MedTwitter#Cirrhosis#Hepatology@my_UEG@LiverFellow
🌍 WHO issues its first global guidelines on child & adolescent obesity. 📈
170M aged 5–19 lived with obesity in 2024. 🧒 Lifestyle care is key; 💊 meds & 🏥 surgery may be considered for selected adolescents. 🔗
https://t.co/UnNLMNmgIG
#MedTwitter#GiTwitter#MedEd@WHO
Would you give a promotility agent to a patient when dealing with a foreign body? Host @iangralnek & guest Henriette Heinrich agree on their approach.
For more practical tips & tricks from their podcast search...
➡️➡️ Endoscopy Unplugged ⬅️⬅️
...wherever you get your podcasts!
✨In case you missed the October ESGE eNewsletter it features:
🔹Abstracts opening
🔹Applications for Research Camp & ESGE-PENTAX Research Grant close soon
🔹ESGE at UEG Week
🔹ESGE Academy Video Journal #6
🔹EU-ENDOHEP survey closing soon
… & more!
👉https://t.co/EaGjNqT83y
GLP1 use may result in about 1 extra case of NAION for every 5,000 people treated for a year.
I break down the numbers and more in this week's #substanceovernoise: https://t.co/0aGMtdDTxr.